» Articles » PMID: 34452512

SARS-CoV-2 Seroprevalence Structure of the Russian Population During the COVID-19 Pandemic

Abstract

The SARS-CoV-2 pandemic, which came to Russia in March 2020, is accompanied by morbidity level changes and can be tracked using serological monitoring of a representative population sample from Federal Districts (FDs) and individual regions. In a longitudinal cohort study conducted in 26 model regions of Russia, distributed across all FDs, we investigated the distribution and cumulative proportions of individuals with antibodies (Abs) to the SARS-CoV-2 nucleocapsid antigen (Ag), in the period from June to December 2020, using a three-phase monitoring process. In addition, during the formation of the cohort of volunteers, the number of seropositive convalescents, persons who had contact with patients or COVID-19 convalescents, and the prevalence of asymptomatic forms of infection among seropositive volunteers were determined. According to a uniform methodology, 3 mL of blood was taken from the examined individuals, and plasma was separated, from which the presence of Abs to nucleocapsid Ag was determined on a Thermo Scientific Multiascan FC device using the "ELISA anti-SARS-CoV-2 IgG" reagent set (prod. Scientific Center for Applied Microbiology and Biotechnology), in accordance with the developer's instructions. Volunteers (74,158) were surveyed and divided into seven age groups (1-17, 18-29, 30-39, 40-49, 59-59, 60-69, and 70+ years old), among whom 14,275 were identified as having antibodies to SARS-CoV-2. The average percent seropositive in Russia was 17.8% (IQR: 8.8-23.2). The largest proportion was found among children under 17 years old (21.6% (IQR: 13.1-31.7). In the remaining groups, seroprevalence ranged from 15.6% (IQR: 8-21.1) to 18.0% (IQR: 13.4-22.6). During monitoring, three (immune) response groups were found: (A) groups with a continuous increase in the proportion of seropositive; (B) those with a slow rate of increase in seroprevalence; and (C) those with a two-phase curve, wherein the initial increase was replaced by a decrease in the percentage of seropositive individuals. A significant correlation was revealed between the number of COVID-19 convalescents and contact persons, and between the number of contacts and healthy seropositive volunteers. Among the seropositive volunteers, more than 93.6% (IQR: 87.1-94.9) were asymptomatic. The results show that the COVID-19 pandemic is accompanied by an increase in seroprevalence, which may be important for the formation of herd immunity.

Citing Articles

Spectrum of COVID-19 cases in Arkhangelsk, Northwest Russia: Findings from a population-based study linking serosurvey, registry data, and self-reports of symptoms.

Krieger E, Kudryavtsev A, Sharashova E, Samodova O, Kontsevaya A, Postoev V PLoS One. 2024; 19(10):e0311287.

PMID: 39392813 PMC: 11469529. DOI: 10.1371/journal.pone.0311287.


SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.

Carreno J, Wagner A, Monahan B, Singh G, Floda D, Gonzalez-Reiche A Nat Commun. 2024; 15(1):5847.

PMID: 38992013 PMC: 11239669. DOI: 10.1038/s41467-024-50052-2.


Seroprevalence of Anti-SARS-CoV-2 Remained Extremely Low in Taiwan Until the Vaccination Program Was Implemented.

Chen Y, Yang M, Lai J, Chen J, Wang Y, Wei S Open Forum Infect Dis. 2024; 11(1):ofad614.

PMID: 38192381 PMC: 10773475. DOI: 10.1093/ofid/ofad614.


COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.

Totolian A, Smirnov V, Krasnov A, Ramsay E, Dedkov V, Popova A Viruses. 2023; 15(11).

PMID: 38005859 PMC: 10675075. DOI: 10.3390/v15112181.


The Development of the SARS-CoV-2 Epidemic in Different Regions of Siberia in the 2020-2022 Period.

Palyanova N, Sobolev I, Palyanov A, Kurskaya O, Komissarov A, Danilenko D Viruses. 2023; 15(10).

PMID: 37896792 PMC: 10612024. DOI: 10.3390/v15102014.


References
1.
Britton T, Ball F, Trapman P . A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science. 2020; 369(6505):846-849. PMC: 7331793. DOI: 10.1126/science.abc6810. View

2.
Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D . Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. Emerg Infect Dis. 2020; 26(9):1978-1986. PMC: 7454079. DOI: 10.3201/eid2609.201840. View

3.
Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View

4.
Khoshchehreh M, Wald-Dickler N, Holtom P, Butler-Wu S . A needle in the haystack? Assessing the significance of envelope (E) gene-negative, nucleocapsid (N2) gene-positive SARS-CoV-2 detection by the Cepheid Xpert Xpress SARS-COV-2 assay. J Clin Virol. 2020; 133:104683. PMC: 7598560. DOI: 10.1016/j.jcv.2020.104683. View

5.
Kuttiatt V, Abraham P, Menon R, Vaidya P, Rahi M . Coronavirus disease 2019 in children: Clinical & epidemiological implications. Indian J Med Res. 2020; 152(1 & 2):21-40. PMC: 7853265. DOI: 10.4103/ijmr.IJMR_977_20. View